Showing 11,601 - 11,620 results of 102,040 for search '(( 5 c decrease ) OR ( 5 ((((point decrease) OR (fold decrease))) OR (a decrease)) ))', query time: 1.86s Refine Results
  1. 11601
  2. 11602
  3. 11603

    Data Sheet 1_Systemic lipid and glucose modulation differentially affects cognitive function and neuroinflammation in a mouse model of Alzheimer’s disease.xlsx by Demos Kynigopoulos (12420457)

    Published 2025
    “…</p>Methods<p>We investigated the effects of two FDA-approved metabolic agents—Alirocumab, a PCSK9 inhibitor that lowers LDL cholesterol, and Gliclazide, a sulfonylurea that enhances insulin secretion—in male 5xFAD mice, a transgenic model of AD. …”
  4. 11604

    Supplementary file 1_Systemic lipid and glucose modulation differentially affects cognitive function and neuroinflammation in a mouse model of Alzheimer’s disease.docx by Demos Kynigopoulos (12420457)

    Published 2025
    “…</p>Methods<p>We investigated the effects of two FDA-approved metabolic agents—Alirocumab, a PCSK9 inhibitor that lowers LDL cholesterol, and Gliclazide, a sulfonylurea that enhances insulin secretion—in male 5xFAD mice, a transgenic model of AD. …”
  5. 11605
  6. 11606
  7. 11607

    Supplementary Material for: Pregnane-Oximino-Alkyl-Amino-Ether Compound as a Novel Class of TGR5 Receptor Agonist Exhibiting Antidiabetic and Anti-Dyslipidemic Activities by Gupta J. (11745866)

    Published 2021
    “…These beneficial effects of compound <b>14b</b> were associated with the activation of the G-protein-coupled bile acid receptor TGR5. <b><i>Conclusion:</i></b> Compound <b>14b</b> exhibits antidiabetic and anti-dyslipidemic activities through activating the TGR5 receptor system and can be developed as a lead for the management of type II diabetes and related metabolic complications.…”
  8. 11608
  9. 11609
  10. 11610
  11. 11611
  12. 11612
  13. 11613
  14. 11614
  15. 11615
  16. 11616
  17. 11617
  18. 11618
  19. 11619
  20. 11620